Department of Internal Medicine, Seoul National University, College of Medicine, Seoul National University Bundang Hospital, Gumi-dong 300, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea.
J Clin Virol. 2011 Aug;51(4):241-5. doi: 10.1016/j.jcv.2011.05.004. Epub 2011 May 31.
Hepatitis B virus (HBV) infection can be associated with non-Hodgkin's lymphoma (NHL), and prophylactic antiviral therapy is recommended for NHL patients with chronic HBV infection who are receiving anticancer chemotherapy.
The aims of this study were to investigate the association between HBV infection and NHL, and to evaluate the application rate and the effect of prophylactic antiviral therapy for HBV-infected NHL patients.
A retrospective, case-control study was performed.
The prevalence of hepatitis B surface antigen in 344 patients who were consecutively diagnosed with NHL from May 2003 to October 2009 (44 of 344; 12.8%) was significantly higher than that of 688 age- and sex-matched health-check examinees (24 of 688; 3.5%) (adjusted odds ratio, 4.08; 95% confidence interval, 2.44-6.85). T cell type NHL, as well as B cell type, showed a significant association with HBV carrier rate. Among 32 NHL patients who received anticancer chemotherapy, 30 patients (93.8%) received prophylactic antiviral therapy, primarily lamivudine. However, HBV DNA monitoring during antiviral therapy was frequently omitted in hemato-oncology clinics. While there was no occurrence of hepatitis flare during antiviral therapy, withdrawal hepatitis after discontinuation of antiviral drug occurred frequently (60%).
HBV may play a significant role in development of NHL, which prompts further study on the lymphomagenic mechanism of HBV infection. Prophylactic antiviral therapy was administered during chemotherapy to almost all of the NHL patients with HBV infection; however, further investigation should be conducted for determination of optimal duration and monitoring of antiviral therapy.
乙型肝炎病毒（HBV）感染可与非霍奇金淋巴瘤（NHL）相关，对于接受抗癌化疗的慢性 HBV 感染 NHL 患者，建议进行预防性抗病毒治疗。
本研究旨在探讨 HBV 感染与 NHL 之间的关联，并评估预防性抗病毒治疗在 HBV 感染 NHL 患者中的应用率和效果。
本研究采用回顾性病例对照研究。
2003 年 5 月至 2009 年 10 月连续诊断为 NHL 的 344 例患者中，乙型肝炎表面抗原的检出率（44/344；12.8%）明显高于同期 688 例年龄和性别匹配的健康检查者（24/688；3.5%）（校正比值比，4.08；95%置信区间，2.44-6.85）。T 细胞型 NHL 以及 B 细胞型 NHL 与 HBV 携带者率均呈显著相关。在接受抗癌化疗的 32 例 NHL 患者中，有 30 例（93.8%）接受了预防性抗病毒治疗，主要是拉米夫定。然而，在血液肿瘤科门诊中，抗病毒治疗期间的 HBV DNA 监测经常被忽略。虽然在抗病毒治疗期间未发生肝炎发作，但停药后常发生停药后肝炎（60%）。
HBV 可能在 NHL 的发生中起重要作用，这促使我们进一步研究 HBV 感染的淋巴瘤发生机制。对于所有 HBV 感染的 NHL 患者，在化疗期间都进行了预防性抗病毒治疗；但是，需要进一步研究以确定最佳的治疗持续时间和抗病毒治疗的监测。
